Disruption of Irisin Dimerization by FDA-Approved Drugs: A Computational Repurposing Approach for the Potential Treatment of Lipodystrophy Syndromes.

Flori, Lorenzo; Brogi, Simone; Sirous, Hajar; Calderone, Vincenzo

Flori, Lorenzo; Brogi, Simone; Sirous, Hajar; Calderone, Vincenzo.

Afiliação

Flori L; Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.
Brogi S; Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.
Sirous H; Bioinformatics Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan 81746-73461, Iran.
Calderone V; Bioinformatics Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan 81746-73461, Iran.

Int J Mol Sci ; 24(8)2023 Apr 20.

Article em En | MEDLINE | ID: mdl-37108741

Assuntos

Fibronectinas; Lipodistrofia; Humanos; Simulação de Acoplamento Molecular; Dimerização; Reposicionamento de Medicamentos; Síndrome; Simulação de Dinâmica Molecular

Palavras-chave

FDA-approved drugs; computational methods; drug repurposing; irisin; lipodystrophy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibronectinas / Lipodistrofia Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google